• Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study on Enzalutamide for Patients with Localized Prostate Cancer Undergoing Robotic-Assisted Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

  • Study on Anifrolumab and Phototherapy for Adults with Progressive Vitiligo

    Not recruiting

    2 1 1
    Investigated Drugs:
    France

  • Study of trastuzumab deruxtecan treatment in patients with advanced HER2-positive breast cancer with or without brain metastases

    Not recruiting

    3 1 1
    Investigated Drugs:
    Belgium Denmark Germany Ireland Italy Poland +2

  • Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

    Not recruiting

    3 1
    Investigated Drugs:
    Bulgaria France Germany Greece Hungary Italy +1

  • Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium

  • Study on Preventing Respiratory Infections in Elderly Patients Using OM85

    Not recruiting

    3 1 1
    Italy

  • Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still’s Disease or Systemic Lupus Erythematosus

    Not recruiting

    4 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Italy The Netherlands

  • Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Germany Italy

  • Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM)

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Spain

powered by